IDEMIA
25.3.2021 09:02:05 CET | Business Wire | Press release
This partnership increases value for eService providers and citizens by offering strong mobile authentication and digital signatures. It enables reliable and convenient access to eServices regardless of location, by turning a citizen’s smartphone or tablet into a highly-secure authentication and signing device.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210325005345/en/
Cybernetica’s technology, SplitKey, complements IDEMIA’s digital ID solutions based on biometrics in order to better meet the diverse needs of governments with a mobile-app and cloud-based approach. These solutions enable secure authentication and qualified signatures in accordance with the EU regulation (eIDAS).
SplitKey uses innovative cryptographic solutions. To ensure security, authentication and signing are only successful when all parts of the person’s credentials (i.e. private keys) - stored between their smart device and the SplitKey host's server - act together across the devices. SplitKey currently assures 70 million transactions a month all over Europe, made by millions of users across hundreds of eServices.
IDEMIA’s digital ID solution, IDway, facilitates ID issuance and authentication and is customizable to meet specific national technical and regulatory requirements. Governments can issue an airtight digital ID based on a national database or ID document.
“We welcome the synergy of combining Cybernetica ’s unique expertise in developing digital identity technology with IDEMIA ’s outstanding position around the world. We are focused on delivering technology that helps people securely interact in an increasingly connected world. Our partnership with IDEMIA, the global leader in Augmented Identity, is a step towards the widespread use of secure mobile authentication and digital signing services globally,” said Oliver Väärtnõu , Chairman of the Management Board at Cybernetica.
”We are delighted to partner with Cybernetica, whose unique role in building the eGovernance ecosystem in Estonia is a global reference. Establishing a secure authentication and eSignature via smartphones is becoming increasingly sought after by many citizens. Cybernetica’s technology fits perfectly with our Digital ID solutions so that we can always support governments as they roll out trusted ID systems among their populations.” said Pierre Lelièvre , IDEMIA Senior Vice President Digital Identity - Public Security & Identity.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
About Cybernetica
Cybernetica has over 20-years of experience in building future-proof products that rely on research and development. The company has had an integral role in building Estonia’s unique e-governance ecosystem, notably the digital identity and secure data exchange infrastructure, and the secure internet voting system. In the digital identity space, the company developed the concept for the original ID-card infrastructure along with supporting legislation in Estonia and has consulted various governments on the topic. SplitKey technology was created by combining Cybernetica’s experiences in the digital identity domain and strength in research and development in cryptography. Currently Cybernetica’s technologies are used in 35 countries all over the world, from Asia to North America to the Caribbean and more.
For more information on Cybernetica, visit cyber.ee / Follow @cybernetica on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005345/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
